- Cummins back, Marsh and Head out of Pakistan ODI series
- Shanghai stocks swing after stimulus briefing as most of Asia rises
- New Zealand's Latham promises 'no fear' as he takes charge for India Tests
- Kyrgios vows to 'shut up' doubters with December comeback
- Public hearings start into death of Brit by Russian nerve agent
- Ex-Stasi officer faces verdict over 1974 Berlin border killing
- Role of government, poverty research tipped for economics Nobel
- 'Stolen satire' feeds US election misinformation
- Rookie McCarty captures first PGA Tour title in Black Desert Championship
- Australia all-rounder Green ruled out of India Test series
- Seeing double in Nigeria's 'twins capital of the world'
- UK FM to attend EU foreign affairs talks for first time in 2 years
- Carter, Billups among 13 new Basketball Hall of Fame inductees
- Ravens rip Commanders as Lions lose NFL sacks leader in win
- Hezbollah drone strike kills four, wounds dozens at Israeli base
- China says launches military drills around Taiwan
- Stewart leads Liberty past Lynx to level WNBA Finals
- England return to winning ways in Nations League, Austria thrash Norway
- UN chief says attacks on UNIFIL 'may constitute a war crime'
- Ravens outlast Commanders while Bucs batter Saints in NFL
- Dozens hurt in Israel as Hezbollah claims drone strike
- England deserve 'world class' coach: Carsley
- Burkina Faso win to become first qualifiers for 2025 AFCON
- AC Milan's Pulisic among five out for USA match in Mexico
- France's Amandine Henry retires from international football
- Centre-left set to win pro-Ukraine Lithuania's vote
- India's World Cup hopes in Pakistan hands after Australia defeat
- Zelensky says NKorea sending troops to Russian army
- England beat Finland to get back on track
- King and Lewis propel West Indies to T20 triumph over Sri Lanka
- Pre-Halloween 'Terrifier' lands atop North America box office
- 'I still plan to compete and play next season,' says Djokovic
- Harris, Trump seek advantage in knife-edge election battle
- Chepngetich shatters women's marathon world record in Chicago
- Kamindu and Asalanka power Sri Lanka to 179 against West Indies
- Chepngetich shatters women's marathon world record as Korir wins in Chicago
- Spain send injured Yamal home 'to prioritise player's health'
- In milestone, SpaceX 'catches' megarocket booster after test flight
- Iraq walks fine line with pro-Iran factions to avoid war
- Race four abandoned after New Zealand breeze into 3-0 lead in America's Cup
- West Indies win toss, put Sri Lanka in to bat in first T20
- Sudan rescuers say air strike killed 23 in Khartoum market
- Netanyahu tells UN to move Lebanon peacekeepers out of 'harm's way'
- Bangladeshi Hindus defy attack worries to celebrate festival
- Kiwis three up in America's Cup as Ineos pay for time penalty
- In a first, SpaceX 'catches' megarocket booster after test flight
- Dominant England crush Scotland at Women's T20 World Cup
- Dropped: The rise and fall of Pakistan batting maestro Babar Azam
- Israel fights Hezbollah on the ground, pounds Lebanon from the air
- Sabalenka outlasts local hero Zheng to win third Wuhan Open title
Moderna CEO says melanoma vaccine could be available by 2025
Moderna CEO Stephane Bancel told AFP his company's experimental vaccine against melanoma could be available in as little as two years, in what would amount to a landmark step against the most serious form of skin cancer.
Globally there were an estimated 325,000 new melanoma cases and 57 ,000 deaths from the disease in 2020.
"We think that in some countries the product could be launched under accelerated approval by 2025," he said in an interview.
Unlike conventional vaccines, so-called therapeutic vaccines treat rather than prevent a disease. But they also work by training the body's own immune system against the invader.
Therapeutic vaccines today represent a real hope in oncology, an "immunotherapy 2.0," according to Bancel.
Moderna's aspirations received a boost Thursday with the latest clinical trial results showing an improvement over time in the chances of survival thanks to the vaccine, which uses the same messenger RNA technology that proved highly effective against serious forms of Covid-19.
In a study involving 157 people with advanced melanoma, the Moderna vaccine in combination with Merck's immunotherapy drug Keytruda reduced the risk of recurrence or death by 49 percent over a period of three years, compared with Keytruda alone.
Moderna had already announced two-year monitoring results last year, which showed a risk reduction of 44 percent.
"The difference in survival is growing. The more time passes, the more you see that advantage" said Bancel, noting that the rate of side effects hadn't increased.
"We have one in two people, compared to the best product on the market, who survive," he said, "which in oncology is huge."
- Seeking early approval -
The existing clinical evidence could thus form the basis for conditional approval of the vaccine, for now known as mRNA-4157, said Bancel.
Under this scenario, a larger, "phase three" study involving a thousand people that Moderna is carrying out in 2024 could confirm the earlier conditional authorization.
Both the US Food and Drug Administration and the European Medicines Agency have placed the therapy on an expedited review pathway.
The vaccine's development begins with sequencing the genome of each patient's tumor and identifying specific mutations to encode against. It is thus an example of "individualized" medicine tailored "just for you," said Bancel.
To prepare for market launch, Moderna is building a new factory in Massachusetts in order to have plentiful supply, a requirement of the FDA.
It also announced Monday that it was starting a phase 3 trial for an mRNA vaccine against lung cancer. Other types of tumors are also being studied.
Bancel's hope is to eventually pair these cancer vaccines with "liquid biopsies" -- groundbreaking tests that detect signs of tumors earlier, via blood tests, and are starting to become available in the United States.
The faster you can detect cancer, the better Moderna's new drugs will work, Bancel believes.
Other companies, such as BioNTech, are also working on individualized therapeutic cancer vaccines.
L.Mason--AMWN